

SIGMA TAU FINANZIARIA SPA

Form 4

June 21, 2010

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
SIGMA TAU FINANZIARIA SPA

2. Issuer Name **and** Ticker or Trading Symbol
SOLIGENIX, INC. [SNGX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
VIA SUDAFRICA, 20,
 (Street)

3. Date of Earliest Transaction
 (Month/Day/Year)
06/18/2010

____ Director ____ ☒ 10% Owner
 ____ Officer (give title below) ____ Other (specify below)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ____ Form filed by One Reporting Person
☒ Form filed by More than One Reporting Person

ROME, L6 00144

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
Common Stock	06/18/2010		P	8,608,580 A	\$ 0.205 54,227,816 I ⁽¹⁾	Indirect ⁽¹⁾	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: SIGMA TAU FINANZIARIA SPA - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrant (right to buy)	\$ 0.28	06/18/2010		J ⁽²⁾		1		06/18/2010	06/18/2015 ⁽³⁾	Common Stock	5,165,148

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SIGMA TAU FINANZIARIA SPA VIA SUDAFRICA, 20 ROME, L6 00144		X		
SIGMA TAU INTERNATIONAL SA 19-21 BOULEVARD DU PRINCE HENRI L-1724, N4 00000		X		
Sigma-Tau America S.A. 19-21 BOULEVARD DU PRINCE HENRI L-1724, N4 00000		X		
Sigma-Tau Pharmaceuticals, Inc. 9841 WASHINGTONIAN BLVD. SUITE 500 GAITHERSBURG, MD 20878		X		

Signatures

/s/ Fabio Amabile,
Attorney-in-fact

06/21/2010

 **Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares directly owned by Sigma-Tau Pharmaceuticals, Inc. ("Pharmaceuticals"). Pharmaceuticals is a direct wholly-owned subsidiary of Sigma-Tau America S.A. ("America"). America is a direct wholly-owned subsidiary of Sigma-Tau International S.A. ("International").

Edgar Filing: SIGMA TAU FINANZIARIA SPA - Form 4

International is a direct wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A.

- (2) This warrant was issued by the Issuer to Pharmaceuticals in consideration of Pharmaceuticals' purchase of 8,608,580 shares of common stock on June 18, 2010.

- The expiration date of the warrant may be accelerated at the Issuer's option if the Issuers's common stock meets certain price thresholds
- (3) and the common shares underlying the warrant are registered for resale pursuant to an effective registration statement or are freely transferable without volume restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended.

Remarks:

Exhibit List

Exhibit 24.1 - Sigma-Tau Finanziaria S.p.A. Power of Attorney

Exhibit 24.2 - Sigma-Tau International S.A. Power of Attorney

Exhibit 24.3 - Sigma-Tau America S.A. Power of Attorney

Exhibit 24.4 - Sigma-Tau Pharmaceuticals, Inc. Power of Attorney

Exhibit 99 - Joint Filer Information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.